These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 36205321)
21. [Performance of combined liquid based cytology and HPV nucleic acid test for detecting cervical precancer among women attending screening]. Jiang MY; Feng RM; Wang L; Li TY; Zhang AA; Cui JF; Pan QJ; Zhang X; Liu ML; Gao F; Chen W; Qiao YL Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):750-756. PubMed ID: 30392339 [No Abstract] [Full Text] [Related]
22. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886 [TBL] [Abstract][Full Text] [Related]
23. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16 Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022 [TBL] [Abstract][Full Text] [Related]
24. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology. Castle PE; Eaton B; Reid J; Getman D; Dockter J J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409 [TBL] [Abstract][Full Text] [Related]
25. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study. Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M; Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982 [TBL] [Abstract][Full Text] [Related]
26. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804 [TBL] [Abstract][Full Text] [Related]
27. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969 [TBL] [Abstract][Full Text] [Related]
28. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial. Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews JA Gynecol Oncol; 2023 Mar; 170():143-152. PubMed ID: 36682092 [TBL] [Abstract][Full Text] [Related]
29. Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. Ramírez AT; Sánchez GI; Nedjai B; Agudelo MC; Brentnall AR; Cuschieri K; Castañeda KM; Cuzick J; Lorincz AT; Int J Cancer; 2021 Mar; 148(6):1383-1393. PubMed ID: 33006394 [TBL] [Abstract][Full Text] [Related]
30. DNA methylation testing with S5 for triage of high-risk HPV positive women. Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM; Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862 [TBL] [Abstract][Full Text] [Related]
31. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China. Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450 [TBL] [Abstract][Full Text] [Related]
32. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping. Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626 [TBL] [Abstract][Full Text] [Related]
33. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051 [TBL] [Abstract][Full Text] [Related]
34. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women. Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849 [TBL] [Abstract][Full Text] [Related]
35. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. Ebisch RM; de Kuyper-de Ridder GM; Bosgraaf RP; Massuger LF; IntHout J; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Bulten J; Siebers AG; Bekkers RL; Melchers WJ Int J Cancer; 2016 Aug; 139(3):691-9. PubMed ID: 26991464 [TBL] [Abstract][Full Text] [Related]
36. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. White C; Bakhiet S; Bates M; Keegan H; Pilkington L; Ruttle C; Sharp L; O' Toole S; Fitzpatrick M; Flannelly G; O' Leary JJ; Martin CM Cytopathology; 2016 Aug; 27(4):269-76. PubMed ID: 26932360 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study. Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S; J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593 [TBL] [Abstract][Full Text] [Related]
38. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC; PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281 [TBL] [Abstract][Full Text] [Related]
39. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038 [TBL] [Abstract][Full Text] [Related]
40. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]